A detailed history of Alpha Mark Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 638 shares of LLY stock, worth $477,230. This represents 0.2% of its overall portfolio holdings.

Number of Shares
638
Previous 798 20.05%
Holding current value
$477,230
Previous $722,000 21.75%
% of portfolio
0.2%
Previous 0.25%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$772.14 - $960.02 $123,542 - $153,603
-160 Reduced 20.05%
638 $565,000
Q2 2024

Jul 17, 2024

SELL
$724.87 - $909.04 $211,662 - $265,439
-292 Reduced 26.79%
798 $722,000
Q1 2024

Apr 18, 2024

SELL
$592.2 - $792.28 $75,209 - $100,619
-127 Reduced 10.44%
1,090 $848,000
Q4 2023

Jan 19, 2024

SELL
$525.19 - $619.13 $30,986 - $36,528
-59 Reduced 4.62%
1,217 $709,000
Q3 2023

Oct 31, 2023

SELL
$434.7 - $599.3 $3,477 - $4,794
-8 Reduced 0.62%
1,276 $685,000
Q2 2023

Jul 28, 2023

SELL
$350.74 - $468.98 $5,261 - $7,034
-15 Reduced 1.15%
1,284 $602,000
Q1 2023

May 04, 2023

BUY
$310.63 - $364.82 $931 - $1,094
3 Added 0.23%
1,299 $446,000
Q4 2022

Feb 06, 2023

SELL
$321.55 - $374.67 $64,310 - $74,934
-200 Reduced 13.37%
1,296 $474,000
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $50,105 - $57,100
-169 Reduced 10.15%
1,496 $484,000
Q2 2022

Aug 11, 2022

SELL
$278.73 - $327.27 $9,755 - $11,454
-35 Reduced 2.06%
1,665 $540,000
Q1 2022

May 02, 2022

SELL
$234.69 - $291.66 $46,938 - $58,332
-200 Reduced 10.53%
1,700 $487,000
Q4 2021

Feb 09, 2022

SELL
$224.85 - $279.04 $24,733 - $30,694
-110 Reduced 5.47%
1,900 $525,000
Q3 2021

Nov 05, 2021

SELL
$221.6 - $272.71 $47,644 - $58,632
-215 Reduced 9.66%
2,010 $464,000
Q2 2021

Aug 06, 2021

SELL
$180.55 - $233.54 $18,235 - $23,587
-101 Reduced 4.34%
2,225 $511,000
Q1 2021

Apr 29, 2021

SELL
$164.32 - $212.72 $24,483 - $31,695
-149 Reduced 6.02%
2,326 $434,000
Q4 2020

Feb 01, 2021

SELL
$130.46 - $172.63 $75,014 - $99,262
-575 Reduced 18.85%
2,475 $417,000
Q2 2020

Aug 10, 2020

SELL
$136.42 - $164.18 $23,191 - $27,910
-170 Reduced 5.28%
3,050 $501,000
Q1 2020

Apr 24, 2020

BUY
$119.05 - $147.35 $2,381 - $2,947
20 Added 0.63%
3,220 $447,000
Q4 2019

Feb 07, 2020

BUY
$106.92 - $132.43 $26,730 - $33,107
250 Added 8.47%
3,200 $421,000
Q3 2019

Nov 01, 2019

SELL
$106.79 - $116.16 $15,377 - $16,727
-144 Reduced 4.65%
2,950 $330,000
Q1 2019

May 09, 2019

BUY
$111.31 - $131.02 $30,610 - $36,030
275 Added 9.76%
3,094 $401,000
Q4 2018

Feb 06, 2019

SELL
$105.9 - $118.64 $51,785 - $58,014
-489 Reduced 14.78%
2,819 $326,000
Q2 2018

Aug 03, 2018

SELL
$75.7 - $86.88 $7,418 - $8,514
-98 Reduced 2.88%
3,308 $282,000
Q1 2018

May 09, 2018

SELL
$74.21 - $87.6 $35,175 - $41,522
-474 Reduced 12.22%
3,406 $264,000
Q4 2017

Feb 09, 2018

SELL
$81.94 - $87.89 $75,712 - $81,210
-924 Reduced 19.23%
3,880 $328,000
Q3 2017

Nov 02, 2017

BUY
$77.07 - $85.54 $370,244 - $410,934
4,804
4,804 $411,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $711B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.